Global Cancer Immunotherapy Market Expected to Reach USD 271.2 Billion by 2033 - IMARC Group

Global Cancer Immunotherapy Market Statistics, Outlook and Regional Analysis 2025-2033

The global cancer immunotherapy market size was valued at USD 129.5 Billion in 2024, and it is expected to reach USD 271.2 Billion by 2033, exhibiting a growth rate (CAGR) of 8.6% from 2025 to 2033.

The global market for cancer immunotherapy is growing due to the rising prevalence of cancer. In the US, cancer remains a leading cause of death for the second year in succession and the leading cause of morbidity after heart disease. In addition, cancer immunotherapy relies on the immune system of the body to detect and eliminate cancer cells, making it a highly promising strategy with substantial potential. Besides this, the introduction of treatments such, as monoclonal antibodies and immune checkpoint inhibitors and the development of Chimeric Antigen Receptor T-cell (CAR T cell) therapies have brought advancements in healthcare by broadening treatment choices and providing promising outcomes for patients’ well-being. According to the reports, Loqtorzi (toripalimab-tpzi), developed by Coherus and Junshi Biosciences, targets PD-1 and is approved for nasopharyngeal carcinoma, demonstrating strong survival benefits in clinical trials​.

Concurrently, environmental concerns act as another significant growth-inducing factor, as these treatments often offer a more sustainable and less resource-intensive alternative to traditional therapies like chemotherapy and radiation. This adjustment maintains treatment efficacy while significantly improving the environmental impact. Besides this, immunotherapy drugs are targeted more despite being less invasive than conventional chemotherapy, further reducing the number of side effects and decreasing the burden on the patients, thereby supporting the market expansion. Moreover, the ability of immunotherapies to achieve long-term remission in a few cases is aligned with the surging demand for more sustainable and effective treatments for cancer, which is boosting the market growth. Additionally, the economic incentives and favorable government policies are strengthening the market share by providing funding for research, offering tax breaks, and fast-tracking regulatory approvals to spur the expedited production and availability of immunotherapeutic solutions. For example, WHO, along with its cancer initiatives, is working intensively with more than 75 governments to develop, finance, and implement policies to promote cancer care for all, driving investments and research into immunotherapies, thereby propelling the market forward.

Global Cancer Immunotherapy Market Statistics, By Region

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia-Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share on account of the growing number of patients suffering from cancer, the rising development of bioinformatic tools, and favorable government initiatives.

North America Cancer Immunotherapy Market Trends:

Advanced healthcare infrastructure in North America is driving the demand for cancer immunotherapy, supporting the integration of new technologies. Furthermore, investments made in R&D by various pharmaceutical companies have led to new treatments, supporting the market growth. In 2024, Vertex Pharmaceuticals announced a $4.9 billion acquisition of Alpine Immune Sciences. This deal boosts Vertex's pipeline in innovative immunotherapy treatments, focusing on protein-based approaches​ This further alarms the urgent demand for immunotherapy in the region and drives the market growth. Moreover, the increasing knowledge of immunotherapy benefits patients and healthcare professionals adds to the market growth.

Asia-Pacific Cancer Immunotherapy Market Trends:

The Asia Pacific market is mainly driven by continuous improvements in healthcare infrastructure and increased affordability of advanced therapies. In addition to this, significant government programs that enhance cancer care and increase awareness about immunotherapy are also driving the market demand.

Europe Cancer Immunotherapy Market Trends:

The market is increasing in Europe due to the growing older population, rise in government fundings for cancer research, and advent of advanced therapies. Additionally, the focus on early diagnosis along with personalized medicine in the region is boosting the growth of the market.

Latin America Cancer Immunotherapy Market Trends:

The Latin American market is growing because of the increased investments in oncology research improved healthcare coverage, and partnerships with global pharmaceutical companies. In addition, the growing awareness of enhanced cancer treatments by initiating new therapies are significantly contributing to the market expansion.

Middle East and Africa Cancer Immunotherapy Market Trends:

The market in the Middle East and Africa is rising due to augmented investments in healthcare, new cancer treatment facilities, and government programs. Besides this, better availability of healthcare services, and awareness campaigns, are helping more people accept immunotherapies, thus supporting the market growth.

Top Companies Leading in the Cancer Immunotherapy Industry:

Some of the leading cancer immunotherapy market companies include Amgen Inc., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, GSK plc, Johnson & Johnson, Merck KGaA, Novartis AG, Pfizer Inc., Sanofi S.A, and Seagen Inc., among many others.

• In May 2024, the U.S. FDA approved Imdelltra, a first-in-class T-cell therapy, for adults with small cell lung cancer (ES-SCLC) who have received platinum chemotherapy, reporting an objective response of 40% and median survival of 14.3 months.

Global Cancer Immunotherapy Market Segmentation Coverage

• On the basis of the therapy type, the market has been categorized into monoclonal antibodies, cancer vaccines, checkpoint inhibitors, immunomodulators, and others. The monoclonal antibodies form the largest segment as they target cancer cells without damaging much of the normal tissue. The increasing acceptance of different types of cancer combining antibodies and antibody-drug has been increasing their significance in the immunotherapy field.
• Based on the application, the market is classified into lung cancer, breast cancer, colorectal cancer, melanoma, prostate cancer, head and neck cancer, and others, amongst which lung cancer dominates the market owing to its high mortality rates, urging significant investments in enhanced treatments. Immunotherapies, such as checkpoint inhibitors, have achieved promising results in improving the survival durations, making them a vital alternative for lung cancer treatment.
• On the basis of the end user, the market has been divided into hospitals, cancer research centers, clinics, and others. Among these, hospitals accounts for the majority of market share as they serve as primary centers for cancer treatment. They are equipped with specialized treatment units and skilled professionals, who have access to the comprehensive patient management systems, which makes them pivotal in delivering effective cancer immunotherapy solutions.

Browse IMARC Related Reports on Cancer Immunotherapy Market:

• Japan Cancer Immunotherapy Market Report
   
• United States Cancer Immunotherapy Market Report
   
• Middle East Cancer Immunotherapy Market Report
   
• South Korea Cancer Immunotherapy Market Report
   
• South East Asia Cancer Immunotherapy Market Report